SK Capital Partners Closes Acquisition of IPACKCHEM
SK Capital Partners, LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has completed its previously announced acquisition of IPACKCHEM Group SAS (“IPACKCHEM” or the “Company”), a leader in sustainability-oriented barrier packaging.
Founded in 1987 by Jean-Philippe Morvan as a division of Air Products Group, IPACKCHEM is a leading global supplier of innovative and specialized barrier packaging solutions. IPACKCHEM’s leading market positions in the Crop Protection and Specialty Chemical markets are further underscored by its commitment to providing 100% recyclable plastic barrier packaging. IPACKCHEM is headquartered in Paris, with global operations spanning seven countries and four continents.
IPACKCHEM represents SK’s second investment in the packaging sector. Stephen D’Incelli, Managing Director at SK Capital, stated, "The transaction is a testament to SK’s ability to leverage our global platform to identify leading materials technologies businesses with immense commercial applications. We believe IPACKCHEM is a highly differentiated and sustainability-advantaged business with significant growth potential. We’ve been tremendously impressed by Jean-Philippe and the entire IPACKCHEM management team and we are excited to partner with them to execute our shared strategic objectives.”
Jean-Philippe Morvan, CEO of IPACKCHEM, noted, “We are delighted to partner with SK Capital as we embark on our next phase of growth. We believe their specialty chemicals expertise, functional and operating resources and extensive M&A capabilities will be instrumental in building on our existing strong market positions. Our common ambition is to accelerate organic and acquisitive growth and develop IPACKCHEM into the leading global barrier packaging player for Crop Protection and select Specialty Chemical markets.”
IPACKCHEM’s Board of Directors includes several highly experienced executives, including Rob Tiede, the former CEO of Sonoco Products, Dave Mezzanotte, SK Capital Senior Director and former Chairman and CEO of Coveris, and George Gregory, SK Capital Senior Director and former CEO of Kraton Polymers.
Rob Tiede, former CEO of Sonoco Products, commented, “IPACKCHEM is at the forefront of addressing many of today’s macroeconomic and socioeconomic issues. The Company’s highly specialized packaging products are of extremely high quality, enabling the safe handling and shipping of highly regulated Crop Protection chemicals that allow farmers to feed the world‘s growing population, and are 100% recyclable, helping to address environmental issues.”
Dave Mezzanotte, Senior Director at SK Capital, added, “IPACKCHEM is a global market leader with a technology differentiation that drives cost and sustainability benefits for customers. We see several actionable opportunities to further expand the Company’s addressable markets and to continue providing customers with high-quality and innovative products, as well as best-in-class service, globally.”
Acquisition financing was provided by Alcentra Ltd., Rothschild & Co served as M&A and financial advisor and Kirkland & Ellis acted as legal counsel to SK Capital.
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $11 billion annually, employs more than 16,000 people globally and operates 146 plants in 28 countries. The firm currently has greater than $5 billion of assets under management. For more information, please visit www.skcapitalpartners.com.
About IPACKCHEM
Headquartered in Paris, France, IPACKCHEM is a leading global manufacturer of innovative plastic packaging products (containers, bottles, jerrycans) for the Crop Protection and Specialty Chemicals end markets. The Company’s UN-approved packaging solutions enable users to safely address the transportation and distribution of “hard-to-hold” and hazardous chemicals, while adhering to stringent regulations. IPACKCHEM operates globally through 8 production facilities, employs ~850 people and serves ~1,200 customers in 35 countries. For more information, please visit www.ipackchem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005497/en/
Contact information
Jeremy Milner
BackBay Communications
401-862-9422
jeremy.milner@backbaycommunications.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS16.4.2021 10:00:00 CEST | Press release
Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting showing that the investigational Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib significantly reduced blood neurofilament light chain (NfL) levels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis (MS). Elevated blood NfL levels have been shown to be associated with damage to neurons and inflammation and may predict future brain atrophy and disease progression. “Blood NfL is a biomarker that may allow monitoring of disease activity and treatment response, which could be less burdensome and more sensitive than other standard clinical measures for MS patients,” said Prof. Jens Kuhle, MD, PhD, Head Multiple Sclerosis Centre, University Hospital Basel. “These data provide key insights into the role evobrutinib may play in modulating the clinical course of MS and fur
IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company15.4.2021 22:15:00 CEST | Press release
IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations. In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results. “As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ seri
Algorand and BridgeTower Capital Announce Strategic Partnership15.4.2021 22:14:00 CEST | Press release
BridgeTower Capital, a global private equity firm, focusing on traditional private equity investments and blockchain and DeFi markets, announced today a partnership with Algorand. Algorand, the creator of the world’s first pure proof-of-stake foundational blockchain, is a leading blockchain technology company accelerating the convergence of decentralized and traditional finance. BridgeTower will use Algorand’s technology as the underlying blockchain solution to issuance of the BridgeTower Capital tokenized digital security. It will also use Algorand as a preferred blockchain for BridgeTower products and services. Beyond the elementary requirement of an open, public network, Algorand’s technology enables a set of high performing Layer-1 blockchains that provide security, scalability, complete transaction finality, built in privacy, Co-Chains, and advanced smart contracts. “Algorand was a clear choice given their technology, team and leadership position in the digital marketplace,” said
BridgeTower Capital Launches Security Token Pre-Offering and Announces Global Expansion With Key Partners15.4.2021 18:00:00 CEST | Press release
BridgeTower Capital, a tokenized global private equity firm, has launched a private Security Token Pre-Offering (STO) culminating 12 months of work to purposefully assemble a team of world-class partners to participate in the blockchain infrastructure and services marketplace in the rapidly growing world of decentralized finance (DeFi). BridgeTower also announced it has formed a Zurich-based entity to further expand its current offering of blockchain infrastructure products and services. BridgeTower launched its Private -STO campaign earlier this week, which provides an opportunity for accredited investors to purchase shares in the company in the form of a digital security. BridgeTower has received active participation already and is seeking to raise $200 million in this initial raise. “We are seeing a global confluence of public and private digital finance markets being fueled by the adoption of blockchain technologies. This is creating unique opportunities for those who can assemble
Cryptology Asset Group p.l.c. successfully completes a share capital increase and sale of treasury shares and reviews options for financing further growth15.4.2021 16:49:00 CEST | Press release
Cryptology Asset Group p.l.c. (ISIN: MT0001770107; Ticker: CAP), a leading European investment company for blockchain- and crypto-related business models, has successfully completed its cash capital increase by issuing 128,375 new shares and the additional sale of the entire amount of 31,625 treasury shares to institutional investors. At a fixed price of EUR 200.00 per share each, the Company will receive total gross proceeds of EUR 32.0 million, which will be used to invest in new portfolio companies from the Cryptology pipeline. The Company is also exploring the possible acquisition of crypto assets, such as Bitcoin, as part of its treasury management strategy. To finance further growth, Cryptology is also currently reviewing various options to raise additional capital, such as through the issuance of a convertible or a straight bond. ICF BANK AG has been commissioned to conduct a market review. Management will make the final financing decision based on investor feedback and the prev
Cryptology Asset Group p.l.c. resolves a cash capital increase and sale of treasury shares15.4.2021 16:45:00 CEST | Press release
The Board of Directors of Cryptology Asset Group p.l.c. (ISIN: MT0001770107; Ticker: CAP) today resolved to increase the share capital of the Company by 128,375 new shares and to sell 31,625 treasury shares which is the entire position Cryptology holds of own shares after the buyback done over the last months. Shareholders' subscription rights to the new shares and the treasury shares are excluded. The Company has entered into binding subscription agreements for the entire amount of in total 160,000 shares with several institutional investors. Closing of the transaction is expected for end of April 2021. The capital increase will be carried out in cash contributions and by partially utilizing the existing authorized capital. The share capital of the Company is to be increased from EUR 2,732,500 to EUR 2,860,875 by issuing 128,375 new bearer shares of the Company ("New Shares"). The New Shares will be issued with a pro rata amount of capital stock of EUR 1.00 per share and with full div
A Digital Transformation: Mary Kay Inc. Launches Immersive Virtual Experience Platform Suite 13 TM15.4.2021 15:03:00 CEST | Press release
Global beauty brand Mary Kay Inc. and its Mary Kay Global Design Studio present Suite 13TM, an innovative virtual beauty experience that leverages the use of virtual reality to digitize Mary Kay's first virtual pop-up showroom. Designed with the latest virtual reality technology, the new Suite 13TM offers Mary Kay Independent Beauty Consultants and their customers a 360-degree, 3D beauty experience where users can virtually browse the beauty brand’s portfolio of skin care as well as explore the company and its founder Mary Kay Ash’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005306/en/ The new Suite 13™ offers Mary Kay Independent Beauty Consultants and their customers a 360-degree, 3D beauty experience. (Photo: Mary Kay Inc.) The new Suite 13TM invites users to tour through virtual “rooms”. Upon entering the “Lobby”, users can learn about the Company’s global legacy. The other virtual rooms include the “P